Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study
- PMID: 11003632
- DOI: 10.1053/jhep.2000.17914
Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study
Abstract
The benefits of screening hepatitis B surface antigen (HBsAg)-positive carriers for hepatocellular carcinoma (HCC) in terms of long-term survival have not been established. We conducted a prospective 16-year, population-based cohort study to determine the impact of screening for HCC in 1,487 HBsAg-positive Alaska native carriers with alpha-fetoprotein (AFP) determinations every 6 months. Men and nonpregnant women with an elevated AFP level were evaluated for the presence of HCC by ultrasound (US) examination. The long-term survival rate for patients whose HCC was detected by the screening program was compared with a historical control group of Alaska native patients with HCC from the same population who were clinically diagnosed with HCC between 1969 and October 1982, through a National Cancer Institute-sponsored Cancer Registry. Between October 1982 and December 1998, 26,752 AFP determinations in HBsAg carriers were performed. One or more AFP elevations were found in 61 men and 39 nonpregnant women. HCC was diagnosed in 32 patients (24 men and 8 women). HCC tumors less than 6 cm were found in 23 patients; 22 patients had resections, and 1 patient refused a resection. Compared with 12 patients with hepatitis B virus (HBV)-related HCC diagnosed from 1969 to October 1982, before this program, the 5- and 10-year survival rate for the 32 patients with HCC were 42% (P =.008) and 30% (P =.07), respectively. Five- and 10-year tumor-free survival rates for carriers who had a normal AFP level on initial screening and subsequently developed HCC were 29% (P =.004) and 24% (P =.024), respectively. Screening of HBsAg carriers with semiannual AFP was effective in detecting most HCC tumors at a resectable stage and significantly prolonged survival rates when compared with historical controls in this population.
Similar articles
-
[Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].Z Gastroenterol. 1997 Dec;35(12):1059-67. Z Gastroenterol. 1997. PMID: 9487638 German.
-
Can hepatocellular cancer screening increase the proportion of long-term survivors?Hepatogastroenterology. 2009 Jul-Aug;56(93):1152-6. Hepatogastroenterology. 2009. PMID: 19760960
-
Assessment of alpha-fetoprotein in chronic HBsAg carriers and in HBsAg negative cirrhosis of the liver.Sb Lek. 1993;94(4):311-5. Sb Lek. 1993. PMID: 7527585
-
Markers for hepatocellular carcinoma.Immunol Ser. 1990;53:403-22. Immunol Ser. 1990. PMID: 1713067 Review.
-
[Alpha-fetoprotein: diagnostic value in hepatic disorders].Pol Merkur Lekarski. 2000 Jun;8(48):420-3. Pol Merkur Lekarski. 2000. PMID: 10967924 Review. Polish.
Cited by
-
Health disparities in liver disease: Time to take notice and take action.Hepatology. 2009 Jul;50(1):309-13. doi: 10.1002/hep.22942. Hepatology. 2009. PMID: 19554619 Free PMC article. No abstract available.
-
Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.World J Gastroenterol. 2014 Sep 7;20(33):11595-617. doi: 10.3748/wjg.v20.i33.11595. World J Gastroenterol. 2014. PMID: 25206267 Free PMC article. Review.
-
Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting.Med Oncol. 2015 Jan;32(1):432. doi: 10.1007/s12032-014-0432-7. Epub 2014 Dec 13. Med Oncol. 2015. PMID: 25502085
-
Should AFP (or any biomarkers) be used for HCC surveillance?Curr Hepatol Rep. 2017 Jun;16(2):137-145. doi: 10.1007/s11901-017-0349-7. Epub 2017 Apr 28. Curr Hepatol Rep. 2017. PMID: 29085770 Free PMC article.
-
Serum monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma.Cancer Sci. 2017 Jul;108(7):1432-1439. doi: 10.1111/cas.13261. Epub 2017 Jun 2. Cancer Sci. 2017. PMID: 28418226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical